Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

The prevalence of “risky behaviour” in adults with cystic fibrosis

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

E. M. Westerman, A. H. De Boer, P. P. H. Le Brun, D. J. Touw, A. C

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

The pharmacokinetics and toxicity of morning vs

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis? Darren Shepherd, Yvonne Belessis,

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Transmission of Pseudomonas aeruginosa in children with cystic fibrosis attending summer camps in The Netherlands R.W. Brimicombe, L. Dijkshoorn, T.J.K.

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,

Amyloidosis in cystic fibrosis: A case series

Spontaneous coronary artery dissection associated with coughing

A.H. Gifford Journal of Cystic Fibrosis

Demographics of glucose metabolism in cystic fibrosis

Inhalation solutions — Which ones may be mixed

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Elisabeth P. Dellon, Elaine Chen, Jessica Goggin, Karen Homa, Bruce C

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration Drucy Borowitz, Daniel Gelfond, Karen.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Antine E. Stenbit, Wendy M. Bullington, Julie L. Heh, Patrick A. Flume

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case– control study Maarten Verregghen, Harry G. Heijerman, Monique.

C. L. Vreede, M. C. Berkhout, A. J. Sprij, W. J. Fokkens, H. G. M

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study E.M. Westerman, P.P.H.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Anne K. Swisher, Kathryn Moffett, Linda Baer

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Presentation transcript:

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman Journal of Cystic Fibrosis Volume 7, Issue 1, Pages 79-84 (January 2008) DOI: 10.1016/j.jcf.2007.05.005 Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Individual sputum concentrations of azithromycin (AZM) during dose regimen 1 (500 mg once-daily; day 1) and dose regimen 2 (1000 mg once-weekly; after 1, 2 and 3 months). AZM concentration was determined in spontaneously produced sputum collected on the day before administration of the weekly dose of AZM. Journal of Cystic Fibrosis 2008 7, 79-84DOI: (10.1016/j.jcf.2007.05.005) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions